Wealth Enhancement Advisory Services LLC Takes $353,000 Position in Ultragenyx Pharmaceutical Inc. $RARE

Wealth Enhancement Advisory Services LLC acquired a new stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 8,848 shares of the biopharmaceutical company’s stock, valued at approximately $353,000.

A number of other institutional investors have also added to or reduced their stakes in RARE. GAMMA Investing LLC increased its holdings in Ultragenyx Pharmaceutical by 76.2% during the first quarter. GAMMA Investing LLC now owns 747 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 323 shares during the last quarter. Parallel Advisors LLC increased its holdings in Ultragenyx Pharmaceutical by 1,061.9% during the second quarter. Parallel Advisors LLC now owns 732 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 669 shares during the last quarter. ANTIPODES PARTNERS Ltd acquired a new position in Ultragenyx Pharmaceutical during the first quarter worth $57,000. Headlands Technologies LLC acquired a new position in Ultragenyx Pharmaceutical during the first quarter worth $59,000. Finally, Covestor Ltd increased its holdings in Ultragenyx Pharmaceutical by 86.8% during the first quarter. Covestor Ltd now owns 1,711 shares of the biopharmaceutical company’s stock worth $62,000 after buying an additional 795 shares during the last quarter. 97.67% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the stock. HC Wainwright restated a “buy” rating and set a $80.00 target price on shares of Ultragenyx Pharmaceutical in a report on Tuesday, September 9th. Wedbush reduced their price objective on shares of Ultragenyx Pharmaceutical from $35.00 to $34.00 and set a “neutral” rating for the company in a research report on Monday, July 14th. Morgan Stanley reduced their price objective on shares of Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an “overweight” rating for the company in a research report on Monday, July 14th. Canaccord Genuity Group reduced their price objective on shares of Ultragenyx Pharmaceutical from $136.00 to $128.00 and set a “buy” rating for the company in a research report on Friday, August 8th. Finally, Guggenheim reaffirmed a “buy” rating and set a $64.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Friday, June 20th. Eleven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Ultragenyx Pharmaceutical has an average rating of “Moderate Buy” and a consensus price target of $81.50.

Ultragenyx Pharmaceutical Trading Down 1.5%

Shares of NASDAQ RARE opened at $29.74 on Wednesday. The company has a market cap of $2.87 billion, a price-to-earnings ratio of -5.38 and a beta of 0.21. Ultragenyx Pharmaceutical Inc. has a 12 month low of $25.81 and a 12 month high of $57.99. The stock has a 50-day moving average price of $29.53 and a two-hundred day moving average price of $33.18.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($1.17) EPS for the quarter, topping the consensus estimate of ($1.27) by $0.10. Ultragenyx Pharmaceutical had a negative return on equity of 237.48% and a negative net margin of 87.34%.The firm had revenue of $166.50 million during the quarter, compared to the consensus estimate of $161.37 million. During the same quarter in the previous year, the firm earned ($1.52) earnings per share. The business’s quarterly revenue was up 13.2% on a year-over-year basis. Ultragenyx Pharmaceutical has set its FY 2025 guidance at EPS. On average, sell-side analysts predict that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current year.

Insider Activity

In other news, EVP Karah Herdman Parschauer sold 2,450 shares of the company’s stock in a transaction that occurred on Friday, September 12th. The stock was sold at an average price of $31.17, for a total value of $76,366.50. Following the completion of the transaction, the executive vice president owned 73,271 shares of the company’s stock, valued at $2,283,857.07. This represents a 3.24% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 5.50% of the stock is owned by corporate insiders.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.